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The failure to dis-
tinguish rational
hope from unrea-
sonable hype can
have significant
consequences; pa-
tients can deny
themselves effective
therapy, expose
themselves to seri-
ous side effects, and
be encumbered by
substantial
expenses.hat investigators should be extremely enthusiastic about their research and the
importance of the findings that it yields is to be fully expected. How could they
devote themselves so completely to the uncertain outcome of the pursuit of new
nowledge if they were not passionate? It is also completely predictable that the lay
ress would be highly motivated to inform the public about any medical discoveries. The
ttention that new health care innovations can attract is obviously very desirable. It goes
ithout saying that the lay public, especially those who might be affected by any new
reakthroughs, would be highly receptive to that information. New developments in
edicine are a source of security to the well and a beacon of hope for the ill. The result
s that the media frequently presents new research findings to the public in the best pos-
ible light and in terms of the greatest potential benefit.
The line that separates appropriate presentation of discoveries that generate reasonable
ope from exuberant depiction of research findings that induce unrealistic expectations
or hype) is often blurred. This blurring may be influenced not only by the presentation
ut also by the reception of individuals with serious disease who are particularly sus-
eptible to grasp for remedies. The failure to distinguish rational hope from unrea-
onable hype can have significant consequences; patients can deny themselves effec-
ive therapy, expose themselves to serious side effects, and be encumbered by
ubstantial expenses.
The area of medicine that perhaps best currently typifies the problems in differentiat-
ng hope from hype involves stem cell therapy. A variety of debilitating disorders exist
or which no cure is possible and even palliation is difficult. In terms of cardiovascular
isease, the inability to correct or enhance the function of destroyed myocardium re-
ains one of the last major hurdles to overcome. We have artificial valves, coronary
tents and bypass, implantable cardioverter-defibrillators, and so on, but we are power-
ess in the face of myocardial scar. So, it is not surprising that the notion of regenerating
yocardium with stem cells stimulates enormous excitement in both physicians and pa-
ients. When preliminary experimental and clinical results suggest that stem cell therapy
s feasible and may be beneficial, the findings are optimistically broadcast to the public
nd stoke the fires of enthusiasm. The fact that it is a daunting challenge to achieve the
elivery, engraftment, survival, and effective functioning of cells safely is sometimes lost
n the transmission.
The results of exuberant optimism and unrealistic hope can be seen in the numerous
tem cell clinics that are operative around the world. A quick search under stem cell
herapy on Google reveals over 16 million entries and over 20 pages of listings. Included
re clinics offering umbilical, adipose, and bone marrow stem cells in Asia, Europe, and
ther locations for cardiac and other conditions. One site advertises that they have
reated over 500 cardiac patients. This is despite the fact that the consensus of the scien-
ific and medical communities is that the efficacy and safety of stem cells is unproven at
his time. In nearly every case, the fee for the services is substantial, and since stem cell
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October 19, 2010:1430–1 Editor’s Pageherapy is not approved in the U.S., these patients must
ay for travel and lodging. The long-term potential of
erious adverse effects remains undefined.
The initial reaction to these many stem cell clinics is to
uspect financial motivation. In fact, history is replete
ith examples of medical ruses for unproven therapy
oisted upon desperate patients. So, it would not be sur-
rising if some clinics primarily represent an attempt to
cquire large sums of money. Such clinics would, of
ourse, be contemptible. However, it seems clear that
here are a number of hospitals, clinics, and physicians
ho feel that sufficient data exist to justify the attempt to
reat incurable diseases with stem cells. In some cases, the
hysicians may have convinced themselves that the bene-
ts of stem cell therapy are established, while in others
hey may be uncertain but feel that they must act while
efinite evidence of efficacy is obtained. Nevertheless, even
ere judgment is questionable. Attempts at regenerative
herapy carry significant potential adverse effects such as tera-
omas. Moreover, since the treatment given is uncontrolled
nd nonrandomized, almost no useful data or guidance re-
arding efficacy or safety will be obtained. Thus, patients are
eing administered unproven therapy at some risk and ex-
ense without significant benefit even to society.
While I disapprove of the commercial provision of
tem cells, as I suspect most physicians involved with this
eld do, I suppose I cannot absolutely condemn it. I re-
ently had an interaction with an ischemic cardiomyopa-
hy patient who described Class IV symptoms despite
aximal medical therapy. While searching the Internet
he came across a clinic in Asia that offered stem cell
herapy for heart failure. She was provided with the con-
act information of a number of prior patients, all of
hom reportedly spoke intelligently of the process and
he benefits of treatment. Although her husband (a law-
er) thought she was “crazy,” their physician son opined
hat she had little to lose, and so they traveled to obtain
he stem cells. The treatment was supervised by an
merican-trained physician, was administered in a “spot-
ess” hospital, required 2 weeks, and cost $40,000 to
50,000. Although there was no immediate effect, the
atient stated that her exertional capacity gradually im-
roved over 6 months and has remained so for 4 years, Euch that her husband and son have become believers.
he woman is ever so grateful for her progress, has never
poken to a patient who did not improve after receiving
tem cells at this hospital, and would go back for addi-
ional treatment if she were able. While I have no idea of
he nature or the mechanism of such improvement, and
bviously cannot rule out a placebo effect, I cannot ques-
ion that the patient is happier and less symptomatic than
efore treatment. In this regard, the nature and mecha-
ism of benefit are probably not of great relevance.
Given the circumstances of investigators and patients, it
s perhaps not surprising that there is often a thin line
etween hope and hype. In my opinion, as researchers we
ave the responsibility to temper overly optimistic inter-
retation of our findings; as clinicians we have the re-
ponsibility to only administer therapies of established
alue except under investigational protocols. Stem cell
herapy represents an issue where the enthusiasm is very
igh and the medical need very great. The result has been
plethora of worldwide medical facilities that administer
tem cell preparations of unproven value to patients with
ebilitating disorders. Not only is such therapy based
pon unfounded expectations, it is expensive and does not
ove us closer to an understanding of the true efficacy of
he treatment. Were stem cells free of any significant side
ffects, I would agree that desperate patients should be
ntitled to try any remedy possible; clearly, there are pa-
ients that have benefited subjectively after such treat-
ents. However, the safety cannot be assured at this
ime. Therefore, I think it is our responsibility to make
ure that our patients have all the facts available, and that
e do everything possible to ensure that the claims made
y these clinics reflect these facts. We have an important
ole in preventing hype and helping our patients distin-
uish hype from hope.
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